Apellis Pharmaceuticals Inc (NASDAQ: APLS) on Monday, plunged -0.93% from the previous trading day, before settling in for the closing price of $18.20. Within the past 52 weeks, APLS’s price has moved between $17.49 and $50.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 92.54%. The company achieved an average annual earnings per share of 36.59%. With a float of $104.48 million, this company’s outstanding shares have now reached $124.50 million.
Let’s determine the extent of company efficiency that accounts for 710 employees. In terms of profitability, gross margin is 84.82%, operating margin of -21.11%, and the pretax margin is -25.18%.
Apellis Pharmaceuticals Inc (APLS) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Apellis Pharmaceuticals Inc is 16.76%, while institutional ownership is 99.61%. The most recent insider transaction that took place on Mar 17 ’25, was worth 4,543. In this transaction VP/Chief Accounting Officer of this company sold 183 shares at a rate of $24.82, taking the stock ownership to the 47,955 shares. Before that another transaction happened on Mar 17 ’25, when Company’s Officer proposed sale 183 for $24.82, making the entire transaction worth $4,543.
Apellis Pharmaceuticals Inc (APLS) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 36.59% per share during the next fiscal year.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Apellis Pharmaceuticals Inc (APLS) is currently performing well based on its current performance indicators. A quick ratio of 3.81 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.60, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach 0.15 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc (APLS)
Looking closely at Apellis Pharmaceuticals Inc (NASDAQ: APLS), its last 5-days average volume was 2.07 million, which is a jump from its year-to-date volume of 2.01 million. As of the previous 9 days, the stock’s Stochastic %D was 21.98%. Additionally, its Average True Range was 1.34.
During the past 100 days, Apellis Pharmaceuticals Inc’s (APLS) raw stochastic average was set at 2.99%, which indicates a significant decrease from 8.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.00% in the past 14 days, which was higher than the 57.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $24.13, while its 200-day Moving Average is $30.79. However, in the short run, Apellis Pharmaceuticals Inc’s stock first resistance to watch stands at $18.61. Second resistance stands at $19.18. The third major resistance level sits at $19.65. If the price goes on to break the first support level at $17.57, it is likely to go to the next support level at $17.10. Now, if the price goes above the second support level, the third support stands at $16.53.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Key Stats
Market capitalization of the company is 2.26 billion based on 125,516K outstanding shares. Right now, sales total 781,370 K and income totals -197,880 K. The company made 212,530 K in profit during its latest quarter, and -36,350 K in sales during its previous quarter.
